Friday, December 05, 2014 9:27:51 AM
Let us get real: The 'biotechnology' of Plnadai does not have the same quality and demands like those biotechnical products which need the confirmation and permissionm by the FDA. Products, extractions methods etc. of the Plandai is MUCH easier and much more simple than usual biotechnical developments with thousands of clinical reports, proves, etc.
I have studied medicine and have a bit a clue about the product of Plandai. I do not get at all why it should have taken ten years to come to the result that FDA approval is not needed for this extraction products.
For those, who have a bit of understanding for such products, this whole last two years must be a joke - at least regarding the clinical reports, maybe not regarding of the facilities.
However, keeping confidence demands to forget Plandai for some years and avoid to listen to the big wordings and promises of Duffgield since 2011/2012 - and it demands to ignore the amazing salaries Duffield pays to himself - even the company does not produce anything yet but debt!
However, Doffield found his golden egg with PLPL - wondering if shareholder ever find more than pennies here.
Well, PLPL is nothing but a high risk non-revenue penny - since two years and still.
Nothing yet to be thrilled about.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM